# A Study of PRT2527 in Participants With Advanced Solid Tumors

> **NCT05159518** · PHASE1 · COMPLETED · sponsor: **Prelude Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Sarcoma
- Castrate Resistant Prostate Cancer
- Hormone Receptor Positive HER2 Negative Breast Cancer
- Non-small Cell Lung Cancer
- Solid Tumors With Known MYC Amplification

## Interventions

- **DRUG:** PRT2527

## Key facts

- **NCT ID:** NCT05159518
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-14
- **Primary completion:** 2023-12-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05159518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05159518, "A Study of PRT2527 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05159518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*